|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our systematic review confirms that placental cannabis pharmacokinetics has been scarcely investigated and that further research is needed to determine advantages and disadvantages for monitoring maternal THC use or the degree of in utero exposure.
|
28645525 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of trans-del-ta-9-tetrahydrocannabinol (Δ9-THC) in marijuana and other preparations of cannabis are mediated by the endocannabinoid system, which is also briefly introduced.Much variation exists in the current literature regarding the functional changes associated with chronic cannabis use.
|
31364398 |
2019 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cannabinoid receptor 1 (CB<sub>1</sub>) is the principal target of the psychoactive constituent of marijuana, the partial agonist Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC).
|
28678776 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
From these results and concomitant behavioral studies, we conclude that social dysfunctions resulting from excessive intake of ∆9-THC in the increasingly available marijuana products used by male teens may largely reflect circuit defects in PL-PFC networks communicating through endocannabinoid-regulated NMDA receptors.
|
31323660 |
2020 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
THC, CBD, CBN, THC-COOH and 11-OH-THC are the most popular markers of cannabis consumption and abuse.
|
29602054 |
2018 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study focused on 11-nor-9carboxy-Δ9-THC (THC-COOH) and Benzoylecgonine (BE), the most common metabolites of cannabis and cocaine, respectively, present in the domestic sewage entering the wastewater treatment plants.
|
30690404 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we addressed the effects of OEA on the association of alcohol and cannabis, a frequent combination in human alcohol addicts, and whose long-term effects are far from being understood.To this end, OEA (10 mg/kg/day, i.p.) was pharmacologically administered for 5 days/week in a preclinical model of adolescent rats with binge-like consumption (1 day/week) of ethanol (3 g/kg, i.g.) combined or not with acute administrations of Δ<sup>9</sup>-THC (5 mg/kg, i.p.) for 5 weeks.
|
31068789 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A molecularly imprinted polymer (MIP) selective for cannabinoids [Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC), 11-nor-9-carboxy-Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC-COOH), and 11-hydroxy-Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC-OH)] has been synthesized, fully characterized, and applied to the assessment of plasma and urine analysis of marijuana abuse by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).
|
27815614 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Healthy cannabis smokers (N = 18) were administered oxycodone (0, 2.5, and 5.0 mg, PO) with smoked cannabis (0.0, 5.6% Δ<sup>9</sup> tetrahydrocannabinol [THC]) and analgesia was assessed using the Cold-Pressor Test (CPT).
|
29463913 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, there is a need for regulated cannabis markets to develop more effective packaging and labelling standards to allow consumers to effectively titrate their THC intake, with the goal of promoting lower-risk cannabis use.
|
31351756 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to study whether the nicotine delivered via e-CIG acts as "a gateway drug" to the use of cannabis, we analysed the behavioural and molecular effects of 7 weeks' pre-exposure to air (AIR), e-CIGs or CIGs on addiction-related conditioned place preference (CPP) in mice using a sub-threshold (0.01 mg/kg) dose of delta-9-tetrahydrocannabinol (Δ<sup>9</sup>-THC), the principal psychoactive constituent of cannabis.
|
30773388 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fact that not all users develop cognitive impairment suggests a genetic vulnerability to adverse effects of cannabis, which are attributed to action of Δ9-tetrahydrocannabinol (Δ<sup>9</sup>-THC), a cannabis constituent and partial agonist of brain cannabinoid receptor 1.
|
30219209 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with iodine provides an easy access to CBN (1a) from crude extracts and side-cuts of the purification of Δ<sup>9</sup>-THC and CBD from respectively narcotic Cannabis sativa (marijuana) and fiber hemp, substantially expanding the availability of this compound and, in the case of fiber hemp, dissecting it from narcotic phytocannabinoids.
|
29240420 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Frequent and occasional cannabis smokers were recruited as participants for four dosing sessions including one active (6.9% Δ<sup>9</sup> -tetrahydrocannabinol, THC) or placebo cannabis-containing brownie, followed by one active or placebo cigarette, or one active or placebo vaporized cannabis dose.
|
27647820 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose herein a Fast High Pressure Liquid Chromatography (Fast-HPLC-DAD) method which allows the efficient separation of CBN (Cannabinol), CBD (Cannabidiol), THC-A and Δ<sup>9</sup>-THC, the major cannabinoids compounds found in cannabis plants in less than 5 min.
|
30348368 |
2019 |
|
Marijuana Abuse
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Potential drivers for a rising prevalence of cannabis use disorders comprise changes in consumption patterns and increasing levels of THC in available cannabis products.
|
31030057 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mean speed (but not lateral control) significantly differed between groups 30 min after smoking cannabis (p ≤ 0.02); low and high THC groups decreased their speed compared to placebo.
|
31678833 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treating an Htr2b<sup>-/-</sup> knockout mouse with THC resulted in increased aggressive behavior, whereas wild-type mice following THC administration showed decreased aggression in the resident-intruder paradigm, demonstrating that HTR2B variation moderates the effects of cannabis on aggression.
|
29875475 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Parents completed a survey and urine samples were analyzed for cotinine and marijuana metabolites, including 11-hydroxy-Δ9-tetrahydrocannabinol (COOH-THC), by using liquid chromatography-tandem mass spectrometry.
|
30455340 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
During each 12-day dronabinol maintenance phase, participants were allowed to self-administer smoked cannabis containing <1% THC (placebo) or 5.7% THC (active) under forced-choice (drug vs. money) or progressive ratio conditions.
|
29689485 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main active chemical of marijuana (delta-9-tetrahydrocannabinol [THC]) readily crosses the placenta, and cannabinoid receptors have been identified in fetal brain and placenta.
|
31343707 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to determine whether inhalation of cannabis decreases headache and migraine ratings as well as whether gender, type of cannabis (concentrate vs. flower), THC, CBD, or dose contribute to changes in these ratings.
|
31715263 |
2019 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
First, we consider the role of human genetic factors and cannabis strain chemotypic differences in contributing to interindividual variation in the response to cannabinoids, such as THC, and review studies demonstrating that THC-induced impairments in decision-making processes are mediated by actions at prefrontal CB<sub>1</sub> receptors.
|
27639448 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro studies suggest that synthetic cannabinoids in these preparations are potent agonists at central cannabinoid CB1 receptors (CB1Rs), but few investigations have delineated their cellular effects, particularly in comparison with the psychoactive component of marijuana, Δ<sup>9</sup> -tetrahydrocannabinol (Δ<sup>9</sup> -THC).
|
26732435 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
THC concentrations were consistent with the clinical state but not with the known pharmacokinetic properties of cannabis nor of intraperitoneal absorption.
|
29317112 |
2018 |